RGC - Regencell Bioscience Holdings Limited -  [ ]

Ticker Details
Regencell Bioscience Holdings Limited
IPO Date: July 16, 2021
Sector: Healthcare
Industry: Drug Manufacturers
Market Cap: $13.93B
Activated in VL: True
Average Daily Range
Avg Daily Range: $3.03 | 6.60%
Avg Daily Range (30 D): $1.37 | 5.40%
Avg Daily Range (90 D): $2.19 | 7.70%
Institutional Daily Volume
Avg Daily Volume: .16M
Avg Daily Volume (30 D): .13M
Avg Daily Volume (90 D): .32M
Trade Size
Avg Trade Size (Sh.): 57
Avg Trade Size (Sh.) (30 D): 54
Avg Trade Size (Sh.) (90 D): 53
Institutional Trades
Total Institutional Trades: 68
Avg Institutional Trade: $.92M
Avg Institutional Trade (30 D): $.93M
Avg Institutional Trade (90 D): $.78M
Avg Institutional Trade Volume: .27M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $.75M
Avg Closing Trade (30 D): $.75M
Avg Closing Trade (90 D): $.67M
Avg Closing Volume: 82.13K
 
News
Apr 5, 2026 @ 1:16 PM
VinFast, Alcoa, And Regencell Are Among the Top 10...
Source: Nabaparna Bhattacharya
Mar 7, 2026 @ 2:15 AM
Here's Why I Wouldn't Touch Regencell Bioscience W...
Source: Reuben Gregg Brewer
Mar 4, 2026 @ 12:58 AM
Bragar Eagel & Squire, P.C. Continues Investigatio...
Source: Bragar Eagel & Squire, P.C.
Mar 1, 2026 @ 5:03 PM
Forget Regencell Bioscience: This Blue Chip Drug M...
Source: Prosper Junior Bakiny
Feb 1, 2026 @ 7:31 PM
UnitedHealth, Trade Desk, And Unity Are Among Top ...
Source: Nabaparna Bhattacharya
Financials
  TTM Q4 2017 FY 2017
Basic EPS $.72 $.19 $.72
Diluted EPS $.72 $.19 $.72
Revenue $3.16B $861.6M $3.16B
Gross Profit
Net Income / Loss $112.3M $28.9M $112.3M
Operating Income / Loss $271.7M $90.7M $271.7M
Cost of Revenue
Net Cash Flow $-17.7M $39.3M $-17.7M
PE Ratio 40.03    
Splits
Jun 16, 2025 38:1